EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs

Cuicui Guo, Xiaodong Dai, Yulei Du, Xiumei Xiong, Xun Gui

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03794-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Cuicui Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, CTLA-4 Antigen, T-Lymphocytes, Regulatory, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCTLA-4 AntigenT-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesAnimalsMiceHumansReceptors, CCR8NeoplasmsSignal TransductionFemaleXenograft Model Antitumor AssaysMacaca fascicularis

Stichwörter der Autor:innen

ADCCBispecific antibodyImmunotherapyTreg depletionTumor inhibition

Substanzen

Antibodies, BispecificCTLA-4 AntigenReceptors, CCR8CTLA4 protein, humanCCR8 protein, human

Autor:innen und Institutionen

  • Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China.
  • Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China. xun.gui@mabwell.com.

Zitieren

APA

Guo, C., Dai, X., Du, Y., Xiong, X., & Gui, X. (2024). Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03794-3

Vancouver

Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03794-3

BibTeX
@article{Guo2024,
  author = {Guo, Cuicui and Dai, Xiaodong and Du, Yulei and Xiong, Xiumei and Gui, Xun},
  title = {Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03794-3}
}
Kostenlos starten →